
# SouthernBiotech 🗍



# Hamster Anti-Mouse KLRG1

Cat. No.	Format	Size
1807-01	Purified (UNLB)	0.5 mg
1807-02	Fluorescein (FITC)	0.5 mg
1807-08	Biotin (BIOT)	0.5 mg
1807-09	R-phycoerythrin (PE)	0.1 mg
1807-09L	R-phycoerythrin (PE)	0.2 mg
1807-14	Low Endotoxin, Azide-Free, (LE/AF)	0.5 mg



C57BL/6 mouse splenocytes were stained with Hamster Anti-Mouse KLRG1-FITC (SB Cat. 1807-02) and Mouse Anti-Mouse NK1.1-PE (SB Cat. No. 1805-09).

#### **Overview**

Clone	2F1
lsotype	Hamster (Syrian) IgG <sub>2</sub>
Immunogen	IL-2-activated NK cells (A-LAK cells) from B6 (H-2 <sup>b</sup> ) mice
Specificity	Mouse/Human KLRG1; Mr 30-38 kDa
Alternate Name(s)	MAFA, killer cell lectin-like receptor G1, mast cell function-associated-antigen

## **Description**

The monoclonal antibody 2F1 reacts with mouse killer cell lectin-like receptor G1 (KLRG1; formerly known as mouse MAFA), a homodimeric member of the lectin-like type 2 transmembrane receptor family that contain characteristic immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in their cytoplasmic domains. These ITIMs interact with the SH2 domains of protein phosphatases such as SHP-1. The 2F1 antibody stains 30-60% of NK1.1<sup>+</sup>CD3<sup>-</sup> splenocytes, and a small fraction of T cells in all mouse strains tested (C57BL/6, BALB/c, 129/J, C3H.SW, AKR/J, SJL). Cell surface expression of KLRG1 is up-regulated by expression of MHC class I molecules. The effect of MHC class I expression is indirect, and can be mediated by interactions with class I-specific Ly49 inhibitory receptors.

# **Applications**

FC – Quality tested <sup>1-21</sup> IP – Reported in literature <sup>1,2</sup> WB-NR – Reported in literature <sup>2</sup>

#### **Working Dilutions**

Flow Cytometry	Purified (UNLB) antibody	$\leq$ 1 $\mu$ g/10 <sup>6</sup> cells	
	FITC and BIOT conjugates	$\leq$ 1 $\mu$ g/10 <sup>6</sup> cells	
	PE conjugate	$\leq$ 0.2 $\mu$ g/10 <sup>6</sup> cells	
	For flow cytometry, the suggested use of these reagents is in a final volume of 100 $\mu\text{L}$		
Other Applications	Since applications vary, you should determine the optimum working dilution for the product that is appropriate for your specific need.		

For Research Use Only. Not for Diagnostic or Therapeutic Use.

# Handling and Storage

- The purified (UNLB) antibody is supplied as 0.5 mg of purified immunoglobulin in 1.0 mL of borate buffered saline, pH 8.2. No preservatives or amine-containing buffer salts added. Store at 2-8°C.
- The fluorescein (FITC) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN<sub>3</sub>. Store at 2-8°C.
- The biotin (BIOT) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN<sub>3</sub>. Store at 2-8°C.
- The R-phycoerythrin (PE) conjugate is supplied as 0.1 mg in 1.0 mL or 0.2 mg in 2.0 mL of PBS/NaN<sub>3</sub> and a stabilizing agent. Store at 2-8°C. **Do not freeze!**
- The low endotoxin, azide-free (LE/AF) antibody is supplied as 0.5 mg purified immunoglobulin in 1.0 mL of PBS. Contains no preservative; handle under aseptic conditions. Store at 2-8°C or aliquot into smaller volumes and store at -20°C. Avoid multiple freeze / thaw cycles.
- Protect fluorochrome-conjugated forms from light. Reagents are stable for the period shown on the label if stored as directed.

## Warning

Some reagents contain sodium azide. Please refer to product specific SDS.

#### References

- 1. Corral L, Hanke T, Vance RE, Cado D, Raulet DH. NK cell expression of the killer cell lectin-like receptor G1 (KLRG1), the mouse homolog of MAFA, is modulated by MHC class I molecules. Eur J Immunol. 2000;30:920-30. (Immunogen, IP, FC)
- Rosshart S, Hofmann M, Schweier O, Pfaff A, Yoshimoto K, Takeuchi T, et al. Interaction of KLRG1 with E-cadherin: new functional and structural insights. Eur J Immunol. 2008;38:3354-64. (FC, IP, WB)
- 3. Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol. 2003;4:1191-98. (FC)
- Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8<sup>+</sup> T cells. J Clin Invest. 2005;115:1616-26. (FC)
- Castellino F, Germain RN. Chemokine-guided CD4<sup>+</sup> T cell help enhances generation of IL-6Rα<sup>high</sup>IL-7Rα<sup>high</sup> prememory CD8<sup>+</sup> T cells. J Immunol. 2007;178:778-87. (FC)
- 6. Sarkar S, Kalia V, Haining WN, Konieczny BT, Subramaniam S, Ahmed R. Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates. J Exp Med. 2008;205:625-40. (FC)
- Kohlmeier JE, Cookenham T, Miller SC, Roberts AD, Christensen JP, Thomsen AR, et al. CXCR3 directs antigen-specific effector CD4<sup>+</sup> T cell migration to the lung during parainfluenza virus infection. J Immunol. 2009;183:4378-84. (FC)
- 8. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, et al. mTOR regulates memory CD8 T-cell differentiation. Nature. 2009;460:108-13. (FC)
- Grujic M, Bartholdy C, Remy M, Pinschewer DD, Christensen JP, Thomsen AR. The role of CD80/CD86 in generation and maintenance of functional virus-specific CD8<sup>+</sup> T cells in mice infected with lymphocytic choriomeningitis virus. J Immunol. 2010;185:1730-43. (FC)
- Wirth TC, Martin MD, Starbeck-Miller G, Harty JT, Badovinac VP. Secondary CD8<sup>+</sup> T-cell responses are controlled by systemic inflammation. Eur J Immunol. 2011;41:1321-33. (FC)
- 11. Haut LH, Ratcliffe S, Pinto AR, Ertl H. Effect of preexisting immunity to adenovirus on transgene product–specific genital T cell responses on vaccination of mice with a homologous vector. J Infect Dis. 2011;203:1073-81. (FC)
- 12. Wilson JJ, Lin E, Pack CD, Frost EL, Hadley A, Swimm AI, et al. Gamma interferon controls mouse polyomavirus infection in vivo. J Virol. 2011;85:10126-34. (FC)
- 13. Tan X, Sande JL, Putnock JS, Blattman JN, Greenberg PD. Retinoic acid as a vaccine adjuvant enhances CD8<sup>+</sup> T cell response and mucosal protection from viral challenge. J Virol. 2011;85:8316-27. (FC)
- 14. Fransen MF, Sluijter M, Morreau H, Arens R, Melief CJ. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res. 2011;17:2270-80. (FC)
- 15. Kohlmeier JE, Reiley WW, Perona-Wright G, Freeman ML, Yager EJ, Conner LM, et al. Inflammatory chemokine receptors regulate CD8<sup>+</sup> T cell contraction and memory generation following infection. J Exp Med. 2011;208:1621-34. (FC)
- 16. Kim EH, Sullivan JA, Plisch EH, Tejera MM, Jatzek A, Choi KY, et al. Signal integration by Akt regulates CD8 T cell effector and memory differentiation. J Immunol. 2012;188:4305-14. (FC)
- 17. Vareki SM, Harding MJ, Waithman J, Zanker D, Shivji AN, Rytelewski M, et al. Differential regulation of simultaneous antitumor and alloreactive CD8<sup>+</sup> T-cell responses in the same host by rapamycin. Am J Transplant. 2012;12:233-9. (FC)
- Hofstetter AR, Ford ML, Sullivan LĆ, Wilson JJ, Hadley A, Brooks AG, et al. MHC class Ib-restricted CD8 T cells differ in dependence on CD4 T cell help and CD28 costimulation over the course of mouse polyomavirus infection. J Immunol. 2012;188:3071-9. (FC)
- Ferrer IR, Wagener ME, Song M, Ford ML. CD154 blockade alters innate immune cell recruitment and programs alloreactive CD8<sup>+</sup> T cells into KLRG-1<sup>high</sup> short-lived effector T cells. PLoS One. 2012;7(7):e40559. (FC)
- 20. Tan WG, Jin H, West EE, Penaloza-MacMaster P, Wieland A, Zilliox MJ, et al. Comparative analysis of simian immunodeficiency virus Gag-specific effector and memory CD8<sup>+</sup> T cells induced by different adenovirus vectors. J Virol. 2013;87:1359-72. (FC)
- 21. Duraiswamy J, Freeman GJ, Coukos G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res. 2013;73:6900-12. (FC)
- 22. SouthernBiotech unpublished data (FC, Human Reactivity)

Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses.